Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.
AuthorsMitchell, Christopher D
Richards, Susan M
Kinsey, Sally E
Lilleyman, John S
Vora, Ajay J
Eden, Tim O B
AffiliationPaediatric Haematology/Oncology, John Radcliffe Hospital, Oxford, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractCorticosteroids are an essential component of treatment for acute lymphoblastic leukaemia (ALL). Prednisolone is the most commonly used steroid, particularly in the maintenance phase of therapy. There is increasing evidence that, even in equipotent dosage for glucocorticoid effect, dexamethasone has enhanced lymphoblast cytotoxicity and penetration of the central nervous system (CNS) compared with prednisolone. Substitution of dexamethasone for prednisolone in the treatment of ALL might, therefore, result in improved event-free and overall survival. Children with newly diagnosed ALL were randomly assigned to receive either dexamethasone or prednisolone in the induction, consolidation (all received dexamethasone in intensification) and continuation phases of treatment. Among 1603 eligible randomized patients, those receiving dexamethasone had half the risk of isolated CNS relapse (P = 0.0007). Event-free survival was significantly improved with dexamethasone (84.2% vs. 75.6% at 5 years; P = 0.01), with no evidence of differing effects in any subgroup of patients. The use of 6.5 mg/m(2) dexamethasone throughout treatment for ALL led to a significant decrease in the risk of relapse for all risk-groups of patients and, despite the increased toxicity, should now be regarded as part of standard therapy for childhood ALL.
CitationBenefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. 2005, 129 (6):734-45 Br. J. Haematol.
JournalBritish Journal of Haematology
- Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
- Authors: Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg ME, Children's Cancer Group.
- Issue date: 2003 May 15
- Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia.
- Authors: Pui CH, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG, Head DR, Relling MV, Ribeiro RC, Rubnitz JE, Kun LE, Evans WE
- Issue date: 1998 Jul 15
- Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
- Authors: Harker-Murray PD, Thomas AJ, Wagner JE, Weisdorf D, Luo X, DeFor TE, Verneris MR, Dusenbery KE, MacMillan ML, Tolar J, Baker KS, Orchard PJ
- Issue date: 2008 Jun
- No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol.
- Authors: Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, Kamijo T, Isoyama K, Kajiwara M, Sotomatsu M, Sugita K, Sugita K, Maeda M, Yabe H, Kinoshita A, Kaneko T, Hayashi Y, Ikuta K, Hanada R, Tsuchida M
- Issue date: 2005 Sep 20
- Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia?
- Authors: Zheng C, Liu X, Wu J, Cai X, Zhu W, Sun Z
- Issue date: 2010 Oct